RAPGEF4 and diabetic cardiomyopathy: In type 1 diabetes-induced diabetic cardiomyopathy, the protein level of the cAMP effector EPAC2 remains unchanged during the progression of diabetes, but the mRNA levels of EPAC1 and EPAC2 are upregulated in the diabetic myocardium.